All Phenotypes Gt(ROSA)26Sor<tm1(gp80,EGFP)Eces> MGI Mouse

Phenotypes associated with this allele

Jump to	Allelic Composition	Genetic Background	Genotype ID
cn1	Gt(ROSA)26Sor^{tm1(gp80,EGFP)Eces}/Gt(ROSA)26Sor⁺ Cd19^tm1(cre)Cgn/Cd19⁺	either: (involves: 129/Sv * 129P2/OlaHsd * C57BL/6) or (involves: 129/Sv * 129P2/OlaHsd * BALB/c * C57BL/6)	MGI:5004802
cn2	Gt(ROSA)26Sor^{tm1(gp80,EGFP)Eces}/Gt(ROSA)26Sor⁺ Ighg1^tm1(cre)Cgn/Ighg1⁺	either: (involves: 129/Sv * 129P2/OlaHsd * C57BL/6) or (involves: 129/Sv * 129P2/OlaHsd * BALB/c * C57BL/6)	MGI:5004803

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

A representative tumor in the nose of a Gt(ROSA)26Sor^{tm1(gp80,EGFP)Eces}/Gt(ROSA)26Sor⁺ Cd19^tm1(cre)Cgn/Cd19⁺ mouse

growth/size/body

enlarged spleen ( J:172031 )

• in non-immunized and immunized mice starting at 2 to 3 months of age

increased spleen weight ( J:172031 )

mortality/aging

decreased tumor-free survival time ( J:172031 )

• mice succumb to tumors between 7 and 19 months of age

immune system

decreased B cell apoptosis ( J:172031 )

• FAS-induced

enlarged spleen ( J:172031 )

• in non-immunized and immunized mice starting at 2 to 3 months of age

increased spleen weight ( J:172031 )

abnormal class switch recombination ( J:172031 )

• immunization fails to promote production of class-switched IgG1 unlike in wild-type mice

decreased B cell number ( J:172031 )

• mice exhibit fewer IgG1+ B cells compared to in wild-type mice

decreased germinal center B cell number ( J:172031 )

decreased plasma cell number ( J:172031 )

increased B cell number ( J:172031 )

• in the spleen with a slight reduction in the splenic B to T cell ratio

increased marginal zone B cell number ( J:172031 )

increased T cell number ( J:172031 )

increased macrophage cell number ( J:172031 )

absent spleen germinal center ( J:172031 )

• in non-immunized and immunized mice

decreased IgA level ( J:172031 )

• NP-stimulated

increased IgE level ( J:172031 )

• NP-stimulated

decreased IgG1 level ( J:172031 )

• resting and NP-stimulated

decreased IgG2a level ( J:172031 )

• resting and NP-stimulated

decreased IgG3 level ( J:172031 )

• resting and NP-stimulated

neoplasm

increased tumor incidence ( J:172031 )

• mice develop tumors in lymphoid tissues including nasopharynx, armpit, and inguinal region

increased sarcoma incidence ( J:172031 )

• histocytic/dendritic cell sarcoma

increased histiocytic sarcoma incidence ( J:172031 )

hematopoietic system

decreased B cell apoptosis ( J:172031 )

• FAS-induced

enlarged spleen ( J:172031 )

• in non-immunized and immunized mice starting at 2 to 3 months of age

increased spleen weight ( J:172031 )

abnormal class switch recombination ( J:172031 )

• immunization fails to promote production of class-switched IgG1 unlike in wild-type mice

decreased B cell number ( J:172031 )

• mice exhibit fewer IgG1+ B cells compared to in wild-type mice

decreased germinal center B cell number ( J:172031 )

decreased plasma cell number ( J:172031 )

increased B cell number ( J:172031 )

• in the spleen with a slight reduction in the splenic B to T cell ratio

increased marginal zone B cell number ( J:172031 )

increased T cell number ( J:172031 )

increased macrophage cell number ( J:172031 )

absent spleen germinal center ( J:172031 )

• in non-immunized and immunized mice

decreased IgA level ( J:172031 )

• NP-stimulated

increased IgE level ( J:172031 )

• NP-stimulated

decreased IgG1 level ( J:172031 )

• resting and NP-stimulated

decreased IgG2a level ( J:172031 )

• resting and NP-stimulated

decreased IgG3 level ( J:172031 )

• resting and NP-stimulated

cellular

decreased B cell apoptosis ( J:172031 )

• FAS-induced

Allelic Composition	Gt(ROSA)26Sor^{tm1(gp80,EGFP)Eces}/Gt(ROSA)26Sor⁺ Ighg1^tm1(cre)Cgn/Ighg1⁺
Genetic Background	either: (involves: 129/Sv * 129P2/OlaHsd * C57BL/6) or (involves: 129/Sv * 129P2/OlaHsd * BALB/c * C57BL/6)

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sor^{tm1(gp80,EGFP)Eces} mutation (0 available); any Gt(ROSA)26Sor mutation (993 available)
Ighg1^tm1(cre)Cgn mutation (3 available); any Ighg1 mutation (28 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

Splenomegaly and lack of germinal center formation in Gt(ROSA)26Sor^{tm1(gp80,EGFP)Eces}/Gt(ROSA)26Sor⁺ Cd19^tm1(cre)Cgn/Cd19⁺ (left) and Gt(ROSA)26Sor^{tm1(gp80,EGFP)Eces}/Gt(ROSA)26Sor⁺ Ighg1^tm1(cre)Cgn/Ighg1⁺ mice (right)

growth/size/body

enlarged spleen ( J:172031 )

• in non-immunized and immunized mice starting at 2 to 3 months of age

increased spleen weight ( J:172031 )

mortality/aging

decreased tumor-free survival time ( J:172031 )

• mice succumb to tumors between 7 and 19 months of age

immune system

enlarged spleen ( J:172031 )

• in non-immunized and immunized mice starting at 2 to 3 months of age

increased spleen weight ( J:172031 )

abnormal class switch recombination ( J:172031 )

decreased B cell number ( J:172031 )

• mice exhibit fewer IgG1+ B cells compared to in wild-type mice

decreased germinal center B cell number ( J:172031 )

decreased follicular B cell number ( J:172031 )

decreased plasma cell number ( J:172031 )

increased B cell number ( J:172031 )

• in the spleen with a slight reduction in the splenic B to T cell ratio

increased marginal zone B cell number ( J:172031 )

increased macrophage cell number ( J:172031 )

absent spleen germinal center ( J:172031 )

• in non-immunized and immunized mice

decreased IgA level ( J:172031 )

• NP-stimulated

increased IgE level ( J:172031 )

• resting and NP-stimulated

decreased IgG1 level ( J:172031 )

• resting and NP-stimulated

decreased IgG2a level ( J:172031 )

• resting and NP-stimulated

decreased IgG2b level ( J:172031 )

• resting and NP-stimulated

decreased IgG3 level ( J:172031 )

• resting and NP-stimulated

neoplasm

increased tumor incidence ( J:172031 )

• mice develop tumors in lymphoid tissues including nasopharynx, armpit, and inguinal region

increased sarcoma incidence ( J:172031 )

• histocytic/dendritic cell sarcoma

increased histiocytic sarcoma incidence ( J:172031 )

hematopoietic system

enlarged spleen ( J:172031 )

• in non-immunized and immunized mice starting at 2 to 3 months of age

increased spleen weight ( J:172031 )

abnormal class switch recombination ( J:172031 )

decreased B cell number ( J:172031 )

• mice exhibit fewer IgG1+ B cells compared to in wild-type mice

decreased germinal center B cell number ( J:172031 )

decreased follicular B cell number ( J:172031 )

decreased plasma cell number ( J:172031 )

increased B cell number ( J:172031 )

• in the spleen with a slight reduction in the splenic B to T cell ratio

increased marginal zone B cell number ( J:172031 )

increased macrophage cell number ( J:172031 )

absent spleen germinal center ( J:172031 )

• in non-immunized and immunized mice

decreased IgA level ( J:172031 )

• NP-stimulated

increased IgE level ( J:172031 )

• resting and NP-stimulated

decreased IgG1 level ( J:172031 )

• resting and NP-stimulated

decreased IgG2a level ( J:172031 )

• resting and NP-stimulated

decreased IgG2b level ( J:172031 )

• resting and NP-stimulated

decreased IgG3 level ( J:172031 )

• resting and NP-stimulated

Contributing Projects: Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support.	last database update 11/19/2024 MGI 6.24